IMMIX BIOPHARMA INC (IMMX) Forecast, Price Target & Analyst Ratings
NASDAQ:IMMX • US45258H1068
9.29 USD
+0.75 (+8.78%)
At close: Mar 6, 2026
9.07 USD
-0.22 (-2.37%)
Pre-Market: 3/9/2026, 6:22:59 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IMMIX BIOPHARMA INC (IMMX).
Forecast Snapshot
Consensus Price Target
$13.26
+ 42.73% Upside
Next Earnings Forecast
Release DateMar 23, 2026
PeriodQ4 / 2025
EPS Estimate-$0.13
Revenue Estimate
ChartMill Buy Consensus
82.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$13.26
Upside
+ 42.73%
From current price of $9.29 to mean target of $13.26, Based on 8 analyst forecasts
Low
$12.12
Median
$13.26
High
$14.70
Price Target Revisions
1 Month
8.33%
3 Months
62.50%
Price Target Summary
8 analysts have analysed IMMX and the average price target is 13.26 USD. This implies a price increase of 42.73% is expected in the next year compared to the current price of 9.29.
The average price target has been revised upward by 62.5% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
IMMX was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about IMMX.
In the previous month the buy percentage consensus was at a similar level.
IMMX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-09 | Mizuho | Initiate | Outperform |
| 2025-12-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-01 | HC Wainwright & Co. | Initiate | Buy |
| 2023-08-14 | Roth MKM | Reiterate | Buy -> Buy |
| 2023-02-22 | Roth MKM | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 23, 2026
PeriodQ4 / 2025
EPS Estimate-$0.13
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q17.13%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
18.75%
EPS (3 Months)
31.58%
Next Earnings Summary
IMMX is expected to report earnings on 3/23/2026. The consensus EPS estimate for the next earnings is -0.13 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 346.33% | N/A 147.59% | N/A 34.05% | N/A 49.35% | N/A 20.81% | N/A 6.30% | |||||||
| EBITDA YoY % growth | -840K | -450K 46.43% | -1.35M -200.00% | -8.22M -508.89% | -16.136M -96.30% | -22.642M -40.32% | N/A -16.12% | N/A 5.66% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -840K | -450K 46.43% | -1.35M -200.00% | -8.22M -508.89% | -16.141M -96.36% | -22.675M -40.48% | N/A -18.42% | N/A -28.21% | N/A -3.40% | N/A 344.56% | N/A -14.35% | N/A 67.99% | N/A 75.40% | N/A 28.22% | N/A 6.16% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -0.88 -76.55% | N/A 14.46% | N/A 9.67% | N/A 26.00% | N/A 16.89% | N/A 765.85% | N/A -62.27% | N/A 32.04% | N/A 63.24% | N/A 27.93% | N/A 7.39% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.13 17.13% | -0.14 4.80% | -0.15 30.45% | -0.17 27.75% | -0.19 -46.15% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.58M -51.98% | -8.227M -75.69% | -8.442M -25.66% | -9.594M -25.21% | -11.052M -45.81% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
13.04%
EPS Next 5 Year
27.70%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
160.61%
Revenue Next 5 Year
187.26%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
IMMIX BIOPHARMA INC / IMMX Forecast FAQ
Can you provide the average price target for IMMIX BIOPHARMA INC stock?
8 analysts have analysed IMMX and the average price target is 13.26 USD. This implies a price increase of 42.73% is expected in the next year compared to the current price of 9.29.
When does IMMIX BIOPHARMA INC (IMMX) report earnings?
IMMIX BIOPHARMA INC (IMMX) will report earnings on 2026-03-23, after the market close.
What are the consensus estimates for IMMIX BIOPHARMA INC (IMMX) next earnings?
The consensus EPS estimate for the next earnings of IMMIX BIOPHARMA INC (IMMX) is -0.13 USD and the consensus revenue estimate is 0 USD.
How many analysts have analysed IMMIX BIOPHARMA INC (IMMX)?
The number of analysts covering IMMIX BIOPHARMA INC (IMMX) is 8.